TY  - JOUR
A1  - ,  
T1  - The stem cell mobilizer StemEnhance reduces fibrosis and enhances proliferation in Thioacetamide induced-liver cirrhosis in the adult male albino rat
JO  - Eur. J. Anat.
SN  - 1136-4890
Y1  - 2016
VL  - 20
SP  - 37
EP  - 45
UR  - http://www.eurjanat.com/web/paper.php?id=150304no
KW  - Liver cirrhosis
KW  - Thioacetamide
KW  - StemEnhance
KW  - TNF-α 
N2  - StemEnhance (SE) is a haematopoietic stem cell mobilizer deduced from natural planet products. Preclinical studies showed that SE advances cardiovascular muscle recovery and relieves the symptoms and signs of diabetes. However, the efficacy of SE in improving liver cirrhosis has not been investigated. This study was done to assess the helpful effects of SE in a Thioacetamide (TAA)-induced rodent model of liver cirrhosis. Thirty adult male albino rats, 16∼18 weeks old and 210∼240 gm weight, were used in this study. They were divided equally into three groups: 1. normal control group: received saline intraperitoneal injection (i.p.) twice weekly for 12 weeks and served as a control; 2. cirrhosis group: liver cirrhosis was induced by (i.p.) injection of TAA (200 mg/kg body weight) twice a week for 8 weeks and left untreated; 3. cirrhosis/SE group: liver cirrhosis was induced the same way and then treated daily orally with SE at a dose of 300 mg/kg body weight dissolved in distilled water for 4 weeks. All the studied groups were sacrificed 12 weeks after beginning experiments. SE was found to alleviate hepatic fibrosis, improve histopathological changes and enhance hepatocyte proliferation. In addition, TNF-α mRNA expression was down-regulated in TAA-induced cirrhotic livers after SE administration. We conclude that SE has a beneficial role in relieving liver fibrosis and improving liver function in the rat model of liver cirrhosis.
ER  -